All of us are certainly anticipating-and looking forward to-this year’s meeting. The 70th Scientific Sessions will present an exciting range of basic, clinical, and translational research.
Among the many highlights of the 70th Scientific Sessions are the final results of the ACCORD trial. The story from this study continues to add to our understanding of the relationship between glucose control, microvascular complications, and cardiovascular risk. No doubt this story will continue to unfold, and the ACCORD Symposium on the final day of this year’s meeting will be highly anticipated.
Results of the ACCORD Clinical Trial
Tuesday, June 29 – Valencia Ballroom AB/CD
Chair: Denise Simons-Morton, MD, PhD
10:15 a.m.–10:35 a.m. Main Results of the ACCORD Blood Pressure Trial
William C. Cushman, MD
10:35 a.m.–10:55 a.m. Main Results of the ACCORD Lipid Trial
Henry N. Ginsberg, MD
10:55 a.m.–11:15 a.m. Effect of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes after 5 Years of Total Follow-Up
Hertzel C. Gerstein, MD
11:15 a.m.–11:35 a.m. Effect of Intensive Glycemia Treatment on Development and Progression of Microvascular Outcomes in the ACCORD Trial
Faramarz Ismail-Beigi, MD, PhD
11:35 a.m.–11:55 a.m. Effects of Intensive Glycemia and Blood Pressure Treatment and Dyslipidemia Management with Fenofibrate on Progression of Diabetic Retinopathy in the ACCORD Trial
Emily Y. Chew, MD
This year’s sessions also bring a renewed focus on scientific and clinical issues in type 1 diabetes, ranging from transplantation to immunology to the artificial pancreas. In collaboration with the JDRF, the ADA will be hosting a symposium on the developments in closed loop insulin delivery systems (the artificial pancreas) and highlighting work with continuous glucose monitoring and care delivery for those with type 1 diabetes.
Joint ADA/JDRF Symposium—The Artificial Pancreas—A Goal within Reach?
Sunday, June 27 – Room 311
Co-Chairs: Richard M. Bergenstal, MD and Richard A. Insel, MD
2:00 p.m.–2:20 p.m. Are We Closer to Closing the Loop?
Aaron Kowalski, PhD
2:20 p.m.–2:40 p.m. Landmark Continuous Glucose Management Trials—Findings and Implications for Care
William V. Tamborlane, MD
2:40 p.m.–3:00 p.m. Barriers to Continuous Glucose Management Use
Marilyn D. Ritholz, PhD
3:00 p.m.–3:20 p.m. Progress—Results of Overnight Closed-Loop Studies
Roman Hovorka, PhD
3:20 p.m.–4:00 p.m. Questions and Answers
Other notable presentations and highlights include the annual ADA/The Lancet Symposium, discussions of diabetes epidemiology, lipid management in diabetes (just how important is HDL cholesterol?), the role vitamin D plays in type 2 diabetes, and the impact of health reform on diabetes care delivery, to name just a few. As always, we will highlight our national award recipients- those that have served the ADA scientific, clinical and volunteer communities-and we invite you to join us in celebrating their accomplishments.
Joint ADA/The Lancet Symposium
Saturday, June 26 – Valencia Ballroom AB
Co-Chairs: Lin Guo, MPhil and M. Sue Kirkman, MD
8:00 a.m.–8:20 a.m. Diabetes, Fasting Glucose, and Risk of Vascular Disease—A Collaborative Meta-Analysis of 96 Prospective Studies
Nadeem Sarwar, MBBS, MPhil
8:20 a.m.–8:40 a.m. Prandial Inhaled Insulin Plus Basal Insulin Glargine vs. Pre-Mixed Biaspart Insulin for Type 2 Diabetes—A Multicentre Randomised Trial
Daniel L. Lorber, MD
8:40 a.m.–9:00 a.m. Efficacy and Safety of Exenatide Once Weekly vs. Sitagliptin or Pioglitazone as an Adjunct to Metformin for Treatment of Type 2 Diabetes (DURATION-2)—A Randomised Trial
Richard M. Bergenstal, MD
9:00 a.m.–9:20 a.m. Once-Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3)—An Open-Label Randomised Trial
Michaela Diamant, MD, PhD
9:20 a.m.–9:40 a.m. Effect of Dapagliflozin in Patients with Type 2 Diabetes Who have Inadequate Glycaemic Control with Metformin—A Randomised, Double-Blind, Placebo-Controlled Trial
Clifford J. Bailey, MD, PhD
9:40 a.m.–10:00 a.m. Vitamins C and E for Prevention of Pre-Eclampsia in Women with Type 1 Diabetes (DAPIT)—A Randomised Placebo-Controlled Trial
David R. McCance, MD
There are many other presentations and symposia that have grabbed our attention, including programs on diabetes prevention. We hope to gain additional insight into exactly how successful programs like the Diabetes Prevention Program (DPP) can be put in place in our everyday world. We are seeing a great deal of new work on implementation of DPP style interventions, in a wide array of community settings.
We hope you can join us for all or part of this year’s program and sample from more than 140 symposia (featuring over 300 nationally and internationally recognized speakers) and over 2,000 individual abstract presentations. From the Opening Reception at Walt Disney World’s Epcot theme park to our Presidential Poster Session, there’s something for everyone in this year’s program.
|
|
Andrew F. Stewart, MD
Chair, Scientific Sessions
Meeting Planning Commitee |
David Kendall, MD
Chief Scientific & Medical Officer
American Diabetes Association |